NTLA Q4 2025 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+78.8% YoY

Gross Profit

$17M73.9% margin

Operating Income

-$99M-428.9% margin

Net Income

-$96M-416.2% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

+67.0%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$69M

Stock-Based Comp.

$91M

Balance Sheet

Total Assets

$842M

Total Liabilities

$171M

Stockholders' Equity

$671M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$13M	+78.8%
Gross Profit	$17M	$13M	+32.1%
Operating Income	-$99M	-$136M	+27.7%
Net Income	-$96M	-$129M	+25.7%